A proof-of-concept study to investigate the efficacy of heat-inactivated autovaccines in Mycobacterium caprae experimentally challenged goats
Loading...
Download
Official URL
Full text at PDC
Publication date
2022
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Research
Citations
Exportar
Citation
Melgarejo, C., Planas, C., Cobos, A., Arrieta-Villegas, C., Sevilla, I. A., Bezos, J., Moll, X., Espada, Y., Garrido, J. M., Domingo, M., Vidal, E., & Pérez de Val, B. (2022). A proof-of-concept study to investigate the efficacy of heat-inactivated autovaccines in Mycobacterium caprae experimentally challenged goats. Scientific reports, 12(1), 22132. https://doi.org/10.1038/s41598-022-26683-0
Abstract
This study aimed to assess the efficacy of a heat-inactivated Mycobacterium caprae (HIMC) vaccine in goats experimentally challenged with the same strain of M. caprae. Twenty-one goats were divided into three groups of seven: vaccinated with heat-inactivated Mycobacterium bovis (HIMB), with HIMC and unvaccinated. At 7 weeks post-vaccination all animals were endobronchially challenged with M. caprae. Blood samples were collected for immunological assays and clinical signs were recorded throughout the experiment. All goats were euthanized at 9 weeks post-challenge. Gross pathological examination, analysis of lung pathology using computed tomography, and bacterial load quantification in pulmonary lymph nodes (LN) by qPCR were carried out. Only HIMC vaccinated goats showed a significant reduction of lung lesions volume and mycobacterial DNA load in LN compared to unvaccinated controls. Both vaccinated groups showed also a significant reduction of the other pathological parameters, an improved clinical outcome and a higher proportion of IFN-γ-producing central memory T cells after vaccination. The results indicated that homologous vaccination of goats with HIMC induced enhanced protection against M. caprae challenge by reducing lung pathology and bacterial load compared to the heterologous vaccine (HIMB). Further large-scale trials are necessary to assess the efficacy of autovaccines under field conditions
Description
Author contributions
B.P. and E.V. conceived and planned the study. C.M., C.P., A.C., C.A.-V., X.M., Y.E., M.D., E.V. and B.P. performed
the experiments and contributed to data collection. C.M., C.P., Y.E., E.V. and B.P. analysed and interpreted the
data. B.P. and M.D. acquired funding and were in charge of project administration. I.S., J.B. and J.G. provided
resources. C.M., E.V. and B.P. wrote the original draft. I.S., J.B., J.G. and M.D. contributed to writing, reviewing,
and editing the final version of the manuscript.